(1) Since the end of 20 19, the pharmaceutical sales of Hongri Pharmaceutical entered a new era. With the publication of Critical Care Medicine Evaluation of Xuebijing Injection in the Treatment of Severe Community-acquired Pneumonia, and entering the national medical insurance catalogue through negotiation, it will bring new opportunities for the future sales of Xuebijing injection, and the company will continue to promote the academic research of Xuebijing injection and explore the clinical value of the product. The next few years will be a period of concentrated R&D achievements of the company, such as moxifloxacin hydrochloride and sodium chloride injection, ibandronate sodium, PTS, KB, etc. The company will focus on the ICU field to build leading products, continuously reserve high-quality products, realize product landing, and further enrich product structure.
(II) Hongri Pharmaceutical Formula Granules will continue to study the national quality standards, speed up the development of homologous products of medicine and food, and strengthen and improve the development system of formula granules. Combining the advantages of location and origin layout of authentic medicinal materials, we will strengthen the ability of centralized procurement and strive to obtain more competitive cost advantages. Relying on the traceability technology of authentic medicinal materials and products, relying on the advantages of infrared fingerprint detection, creating high-quality brands and expanding the sales scale of Chinese herbal pieces; With the help of the resources of doctors in China and the intelligent diagnosis and treatment of Chinese medicine, the coverage of primary medical market will be improved; The medical and health service business will continue to upgrade the iterative online platform, constantly improve the full collaborative medical service and the China doctor value transformation platform, and form the terminal brand channel of the Group's big health products. Close to the market terminal demand, integrate the products, channels, smart medical care and other self-owned resources of the whole industry chain of formula granules, set up a Chinese medicine business group, and use the company's resource advantages to strengthen brand collaboration.
(3) The medical device business focuses on the family medical market, explores the domestic primary medical market, deepens the international market, integrates the resource-rich product lines at home and abroad, and enhances brand recognition.
(4) Give full play to the resource advantages of the raw materials division, create high-end varieties through multiple channels, improve technical marketing capabilities, enter the international market, and expand product applications in non-pharmaceutical fields.